Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024

January 17, 2025

Saad Z. Usmani, MD, MBA, FACP, FASCO

Opinion

Video

Saad Z. Usmani, MD, MBA, FACP, discusses how the iMMagine-1 trial, presented at ASH 2024, evaluated the novel chimeric antigen receptor (CAR) T-cell therapy anitocabtagene autoleucel, detailing its study objectives, design, and methodology as well as the promising results that highlight its potential to advance treatment options for multiple myeloma.

EP: 1.Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024

EP: 2.Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024

EP: 3.MRD Outcomes From CEPHEUS at ASH 2024

EP: 4.Transplant-Ineligible Myeloma and MRD Integration: Current Definitions and Future Directions

Now Viewing

EP: 5.Anitocabtagene Autoleucel in Focus: Insights From the iMMagine-1 Trial at ASH 2024

EP: 6.Advancing Multiple Myeloma Care: Insights From ASH 2024 and Beyond

Video content above is prompted by the following:

Discuss the novel CAR T-cell therapy anitocabtagene autoleucel, as studied in the iMMagine-1 trial and presented at ASH 2024.
What was the objective of this study?
How was this study designed/what methodology was used?
What results were presented?

Related Content

ICYMI: Highlights From AMCP Nexus 2024

December 26th 2024

Article

Check out this year's top coverage from The Academy of Managed Care Pharmacy (AMCP) Nexus 2024 meeting, which included relevant topics in health care policy, novel pharmaceutical developments, financial considerations across multiple conditions, and more.

ICYMI: Highlights From ASCO 2024

December 21st 2024

Article

Top coverage from the 2024 American Society of Clinical Oncology (ASCO) annual meeting included research topics in non-small cell lung cancer (NSCLC), multiple myeloma, metastatic colorectal cancer (mCRC), and more.

ICYMI: Highlights From SLEEP 2024

December 18th 2024

Article

Check out our top 5 most-viewed pieces of coverage from the 2024 SLEEP meeting.

ICYMI: Highlights From ACTRIMS 2024

December 12th 2024

Article

Read about the diverse array of research presented at this year's meeting, including novel technological advancements and insights into disease progression in multiple sclerosis (MS).